NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs

1. A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Author(s):
Purvis, Leigh, author
Publication:
Washington, D.C. : AARP Public Policy Institute, September 2014
Subject(s):
Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
Drugs, Generic -- economics
Federal Government
State Government
Humans
United States
United States. Food and Drug Administration.
United States.

2. Medicare and mental health: the fundamentals

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Insurance Coverage
Medicare -- economics
Mental Disorders -- economics
Mental Health -- statistics & numerical data
Community Mental Health Services -- economics
Disabled Persons
Disease Management
Drug Costs
Health Expenditures
Hospitalization -- economics
Insurance, Pharmaceutical Services
Medicaid -- economics
Medicare -- statistics & numerical data
Mental Disorders -- epidemiology
Mental Disorders -- therapy
Mental Health Services -- economics
Prevalence
Psychotropic Drugs -- economics
Humans
United States
Medicare Payment Advisory Commission (U.S.)

3. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Armstrong, Katrina A., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Antineoplastic Agents -- economics
Antineoplastic Agents -- therapeutic use
Drug Costs
Financing, Personal -- statistics & numerical data
Medication Adherence -- statistics & numerical data
Administration, Oral
Antineoplastic Agents -- administration & dosage
Health Services Accessibility
Prescription Drugs -- economics
Socioeconomic Factors
Time Factors
Humans
United States

5. The Medi-Cal prescription drug benefit: an overview

Publication:
Oakland, Calif. : California HealthCare Foundation, [2009]
Subject(s):
Health Expenditures -- trends
Insurance Benefits
Insurance, Pharmaceutical Services
Medicaid
Prescription Drugs -- economics
Adult
Aged
Child
Cost Control
Cost Sharing
Disabled Persons
Drug Costs
Drug Utilization Review
Drugs, Generic
Fee-for-Service Plans
Forecasting
Managed Care Programs
Medicare Part D
Middle Aged
Humans
California

6. State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?

Publication:
[Washington, D.C.] : AcademyHealth, [2005]
Subject(s):
Cost Control
Medicare -- economics
State Health Plans -- economics
Cost Sharing
Drug Costs
Drug Utilization Review
Drugs, Generic
Fees, Pharmaceutical
Formularies as Topic
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Humans
United States

8. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

9. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

10. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system